TsITOKINOVYE NARUShENIYa PRI ShIZOFRENII I AFFEKTIVNYKh RASSTROYSTVAKh (ANALITIChESKIY OBZOR)


Cite item

Full Text

Abstract

В настоящее время большое значение придается роли цитокинов в сложных и пока еще недостаточно изученных механизмах интеграции нервной и иммунной систем. В предлагаемом аналитическом обзоре обсуждается роль цитокиновых нарушений в патогенезе шизофрении и аффективных расстройств. Приводятся данные об иммуномодулирующей активности различных классов нейролептиков и антидепрессантов и их влиянии на цитокиновую систему.

Full Text

Restricted Access

About the authors

K. V Kazantseva

References

  1. Александровский Ю.А., Чехонин В.П. Клиническая иммунология пограничных психических расстройств. М., 2005. 256 с.
  2. Акмаев И.Г. Взаимодействие нервных, эндокринных и иммунных механизмов мозга //Журнал невропатологии и психиатрии им. С.С. Корсакова. 1998. Выпуск 3. С. 54-56.
  3. Айтбаева Ж.Т., Еркинбекова Б.К. Параметры регуляторных процессов, опосредованных цитокинами у больных депрессивными расстройствами // Сибирский вестник психиатрии и наркологии. 2008. № 1. С. 51-54.
  4. Ветлугина Т.П., Семке В.Я. Клиническая психонейроиммунология на современном этапе // Сибирский вестник психиатрии и наркологии. 2001. № 3. С. 34-36.
  5. Ветлугина Т.П., Лобачева О.А., Семке А.В. и др. Динамика показателей крови и иммунитета у больных шизофренией в процессе лечения сероквелем (кветиапином) // Сибирский вестник психиатрии и наркологии. 2004. № 4. С. 112-114.
  6. Симбирцев А.С. Цитокины - новая система регуляции защитных реакций организма // Цитокины и воспаление. 2002 № 1. С. 9-17.
  7. Masek K, Slansky J, Petrovicky P, et al. Neuroendocrine immune interactions in health and disease. lnt lmmunopharmacol 2003;3: 1235-46.
  8. Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. lmmunol Cell Biol 2001;79:350-57.
  9. Szelenyi J. Cytokines and the central nervous system. Brain Res Bul 2001;54:329-38.
  10. Schuld A, Kraus T, Haack M, et al. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 2000;43:164-66.
  11. Goehler L.E., Gaykema R.P., Nguyen K.T. et al. lnterleukin-1 beta in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems? J Neurosci 1999;19:2799-806.
  12. Dantzer R, Konsman J.P, Bluthe R.M, et al. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent? Auton. Neurosci 2000;85:60-65.
  13. Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet 1995;345:99-103.
  14. Guellimin G.J, Kerr S.J, Pemberton L.A, et al. lFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res 2001;21:1097-100.
  15. Fabry Z, Fitzsimmons K.M, Herlein J.A, et al. Production of the cytokines interleukin 1 and 6 by murine brain microvessel endothelium and smooth muscle pericytes. J Neuro-immunol 1993;47:23-34.
  16. De Simoni M.G, Imeri L. Cytokine-neuro-transmitter interactions in the brain. Biol Signals Recept 1998;7:33-44.
  17. Kronfol Z, Remick D.G. Cytokines and the brain: lmplications for clinical Psychiatry. Am J Psychiatry 2000;157:683-94.
  18. Sredni-Kenigsbuch D. TH1/TH2 cytokines in the central nervous system. lnt J Neurosci 2002;112:665-703.
  19. Taga T, Fukuda S. Role of IL-6 in the neural stem cell differentiation. Clin Rev Allergy lmmunol 2005;28:249-56.
  20. Banks W.A, Kastin A.J, Durham D.A. Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Res Bull 1989;23:433-37.
  21. Muller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (England) 1998;22(1):1-33.
  22. Schwarz M.J, Chiang S, Muller N, et al. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 2001a;15: 340-70.
  23. Schwarz M.J, Muller N, Riedel M, et al. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001b;56:483-86.
  24. Yao J.K, Sistilli C.G, van Kammen D.P. Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2003;69:429-36.
  25. Zhang X.Y, Zhou D.F, Cao L.Y, et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004;65:940-47.
  26. Schuld A, Hinze-Selch D, Pollma Echer T. Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness. Nervenarzt 2004;75:215-26.
  27. Drzyzga L, Obuchowicz E, Marcinowska A, et al. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006;20:532-45.
  28. Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159: 1029-34.
  29. Kim Y.K, Myint A.M, Lee B.H, et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1129-34.
  30. Cazzullo C.L, Trabattoni D, Saresella M, et al. Research on psychoimmunology. World J Biol Psychiatry 2003;4:119-23.
  31. Zhang X.Y, Zhou D.F, Zhang P.Y, et al. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002;57:247-58.
  32. McAllister C.G, van Kammen D.P, Rehn T.J, et al. Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status. Am J Psychiatry 1995;152:1291-97.
  33. Lin A, Kenis G, Bignotti S, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998;32:9-15.
  34. Toyooka K, Watanabe Y, Iritani S, et al. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci Res 2003; 46:299-307.
  35. Preble O.T, Torrey E.F. Serum interferon in patients with psychosis. Am J Psychiatry 1985; 142:1184-86.
  36. Lu L.X, Guo S.Q, Chen W, et al. Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di Yi Junyi Daxue Xuebao 2004; 24:1251-54.
  37. Kato T, Monjii A, Hashioka S, et al. Risperidone significantly inhibits interferon-γ-in-duced microglial activation in vitro. Schizophrenia Research 2007;92:108-15.
  38. Cortese M. Research on the influence of chlorpromazine on immune processes. Riv Ist Sieroter Ital 1959;34:189-93.
  39. Clancy K.D, Lorenz K, Dries D, et al. Chlorpromazine modulates cytokine expression in the liver and lung after burn injury and endotoxemia. J Trauma 2000;48:215-22.
  40. Mengozzi M, Fantuzzi G, Faggioni R, et al. Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice. Immunology 1994;82:207-10.
  41. Ohtsuka H, Higuchi T, Matsuzawa H, et al. Inhibitory effect on LPS-induced tumor necrosis factor in calves treated with chlorpromazine or pentoxifylline. J Vet Med Sci 1997; 59:1075-77.
  42. Netea M.G, Blok W.L, Kullberg, B.J, et al. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995;171: 393-99.
  43. Labuzek K, Kowalski J, Gabryel B, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol 2005;15:23-30.
  44. Szuster-Ciesielska A, Slotwinska M, Stachura A, et al. Neuroleptics modulatecytokine and reactive oxygen species production in blood leukocytes of healthy volunteers. Arch Immunol Ther Exp 2004;52:59-67.
  45. Kowalski J, Blada P, Kucia K, et al. Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factoralpha from monocytes in schizophrenia. Schizophr Res 2001;50:169-75.
  46. Moots R.J, Al-Saffar Z, Hutchinson D, et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 1999;58:585-87.
  47. Maes M, Meltzer H.Y, Bosmans E. Immune-inflamatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatry Scand 1994;89:346-51.
  48. Pollmaecher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996;16:403-09.
  49. Hinze-Selch D, Mullington J, Pollmaecher T. Clozapine, cytokines, fever and sleep. Wien Med Wochenschr 1996;146:311-13.
  50. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatry Res 1999;33: 407-18.
  51. Valverde A.M, Benito M, Lorenzo M. The brown adipose cell: a model for understanding the molecular mechanism of insulin resistance. Acta Physiol Scand 2005;183:59-73.
  52. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 2002;47:742-49.
  53. Monteleone P, Fabrazzo M, Tortorella A, et al. Pronounced early increase in circulating leptin predicts a lower weightgain during clozapine treatment. J Clin Psychopharmacol 2002;22:424-6.
  54. Song C, Lin A, Kenis G, et al. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 2000; 42:157-64.
  55. Schuld A, Kraus T, Haack M, et al. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 2000;43:164-66.
  56. Schuld A, Hinze-Selch D, Pollmacher T. Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness. Nervenarzt 2004;75:215-26.
  57. Hou Y, Wu C.F, Yang J.Y, et al. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1523-28.
  58. Cazzullo C.L, Sacchetti E, Galluzzo A, et al. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:33-39.
  59. Lieberman J.A, Tollefson G.D, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005;62:361-70.
  60. Girgis R.R, Diwadkar V.A, Nutche J.J, et al. Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study. Schizophr Res 2006;82:89-94.
  61. Block M.L, Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005;76:77-98.
  62. Ikeda K, Hirano M, Orita A, et al. Chlorpromazine inhibits concanavalin A-induced liver injury independently of cytokine modulation. Immunol Lett 1997;55:127-31.
  63. Tarazona R, Gonzalez-Garcia A, Zamzami N, et al. Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 1995;154:861-70.
  64. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002;5:401-12.
  65. Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol 2002;5; 333-43.
  66. Myint A.M, Leonard B.E, Steinbusch H.W, et al. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005; 88: 167-73.
  67. Schiepers O.J, Wichers M.C, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:201-17.
  68. Leonard B.E. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25:767-80.
  69. Maier S.F, Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998;105:83-107.
  70. Capuron L, Ravaud A, Gualde N, et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001;26: 797808.
  71. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferonalpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90.
  72. Larson S.J, Romanoff R.L, Dunn A.J, et al. Effects of interleukin-1beta on foodmaintained behavior in the mouse. Brain Behav Immun 2002;16:398-410.
  73. Schramm T.M, Lawford B.R, Macdonald G.A, et al. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-61.
  74. Kraus M.R, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-99.
  75. Irwin M. Psychoneuroimmunology of depression: clinical implications. Brain Behav Immun 2002;16:1-16.
  76. Pike J.L, Irwin M.R. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun 2006;20:169-74.
  77. Siegert R.J, Abernethy D.A. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005;76:469-75.
  78. Dickens C, McGowan L, Clark-Carter D, et al. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 2002;64:52-60.
  79. Zautra A.J, Yocum D.C, Villanueva I, et al. Immune activation and depression in women with rheumatoid arthritis. J Rheumatol 2004;31:457-63.
  80. Sluzewska A, Rybakowski J.K, Laciak M, et al. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acad Sci 1995a;762:474-76.
  81. Sluzewska A, Rybakowski J.K, Sobieska M, et al. Increased levels of a-1- acidic glycoprotein and interleukin-6 in refractory depression. Depression 1995b;3:170-75.
  82. Maes M, Bosmans E, De Jongh R, et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment-resistant depression. Cytokine 1997; 9:853-58.
  83. Kim Y.K, Na S.K, Shin K.H, et al. Cytokine imbalance in the pathophysiology of major depressive disorder.Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1044-53.
  84. Jun T.Y, Pae C.U, Hoon-Han H, et al. Possible association between-G308A tumour necrosis factor-a gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003;13(3):179-81.
  85. Fertuzinhos S.M, Oliviera J.R, Nishimura A.L, et al. Analysis of IL-1a, IL-1h, and IL-1RA polymorphisms in dysthymia. J Mol Neurosci 2004;22(3):251-56.
  86. Rosa A, Peralta V, Papiol S, et al. Interleukin- 1beta (IL-1h) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. Am J Med Genet 2004;124B(1):10-14.
  87. Rothermundt M, Arolt V, Peters M, et al. Inflammatory markers in major depression and melancholia. J Affect Disord 2001;63 (1-3): 93-102.
  88. Herbert T.B, Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull 1993; 113:472-86.
  89. Zorrilla E.P, Luborsky L, McKay J.R, et al. The relationship of depression and stressors to immunological assays: a metaanalytic review. Brain Behav Immun 2001;15:199-226.
  90. Xia Z, DePierre J.W, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 1996;34:27- 37.
  91. Maes M, Song C, Lin A.H, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferongamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999;20:370-79.
  92. Connor T.J, Harkin A, Kelly J.P, et al. Olfactory bulbectomy provokes a suppression of interleukin-1beta and tumour necrosis factor-alpha production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment. Neuroimmunomodulation 2000;7:27-35.
  93. Kubera M, Maes M. Serotonin-immune interactions in major depression. In: Patterson, Kordon, Christen (Eds.), Neuro-immune Interactions in Neurologic and Psychiatric Disorders. Springer-Verlag, Berlin 2000;79-87.
  94. Mossner R, Daniel S, Schmitt A, et al. Modulation of serotonin transporter function by interleukin-4. Life Sci 2001;68:873-80.
  95. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996;711: 163-74.
  96. Obuchowicz E, Kowalski J, Labuzek K, et al. Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. Int J Neuropsychopharmacol 2006;9:27-35.
  97. Hinze-selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amltriptyline or paroxetine. Neuropsychopharmacology 2000;23:13-19.
  98. Kubera M, Kenis G, Bosmans E, et al. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsy chopharmacology 2000;23:89-98.
  99. Yirmiya R, Weidenfeld J, Pollak Y, et al. Cytokines, "Depression due to a general medical condition", and antidepressant drugs. Adv Exp Med Biol 1996;461:283-316.
  100. Tuglu C, Kara S.H, Caliyurt O, et al. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 2003;170:429-33.
  101. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta 2004;344:1-12.
  102. Kita A, Yamasaki H, Kuwahara H, et al. Identification of the promoter region required for human adiponectin gene transcription: association with CCAAT/enhancer binding protein-beta and tumor necrosis factoralpha. Biochem Biophys Res Commun 2005; 331:484-90.
  103. Hellstrand K, Czerkinsky C, Ricksten A, et al, et al. Role of serotonin in the regulation of interferon-gamma production by human natural killer cells. J Interferon Res 1993;13:33-38.
  104. Young M.R, Kut J.L, Coogan M.P, et al. Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low-dose exogenous serotonin. Immunology 1993;80: 395-400.
  105. Yaron I, Shirazi I, Judovich R, et al. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999;42:2561-68.
  106. Konan K.V, Taylor M.W. Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996;271:1014-50.
  107. Guillemin G.J, Kerr S.J, Pemberton L.A, et al. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res 2001;21:1097-100.
  108. Ha E, Jung K.H, Choe B.K, et al. Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci Lett 2006;397:185-89.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies